Bergmeier W, Bouvard D, Eble JA, Mokhtari-Nejad R, Schulte V, Zirngibl H, Brakebusch C, Fässler R, Nieswandt B (2001) Rhodocytin (aggretin) activates platelets lacking a2b1 integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein Iba. J Biol Chem 276(27): 25121-25126
Brown MC, Eble JA, Calvete JJ, Marcinkiewicz C (2009) Structural requirements of KTS-disintegrins for inhibition of a1b1 integrin. Biochem J 417(1): 95-101
De Santana Evangelista K, Andrich F, Figueiredo De Rezende F, Cordeiro MN, Niland S, Horlacher T, Schmidt-Hederich A, Seeberger P, Sanchez EF, Richardson M, Gomes De Figueiredo S, Eble JA (2010) Plumieribetin, a fish lectin homologous to monocot B-lectins, inhibits the collagen-binding a1b1 integrin. J Biol Chem 284(50): 34747-34758
Eble JA (1997) Integrins - a versatile and old family of cell adhesion molecules. In Integrin-Ligand Interaction, Eble JA, Kühn K (eds), pp 1-40. Heidelberg: Springer-Verlag
Eble JA (2001) The molecular basis of integrin-extracellular matrix interactions. Osteoarthritis and Cartilage 9(Suppl. A): S131-S140
Eble JA (2005) Collagen-binding integrins as pharmaceutical targets. Curr Pharm Design 11: 867-880
Eble JA (2006) Freie Fahrt fürs flüssige Blut: Gerinnungshemmende Wirkstoffe aus Schlangengiften. Chemie in unserer Zeit 40: 326-337
Eble JA (2007) Tumor cell-stroma cell interactions, Chapter 70. In The Cancer Handbook, Alison MR (ed), Vol. 2, pp 970-980. Chichester: John Wiley & Sons
Eble JA (2009) The extracellular matrix in health and disease. Curr Pharm Des 15(12): 5-6
Eble JA (2010) Matrix biology meets toxinology. Matrix Biol 29(4): 239-247
Eble JA, Beermann B, Hinz H-J, Schmidt-Hederich A (2001) a2b1 integrin is not recognized by rhodocytin but is the specific high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen. J Biol Chem 276(15): 12274-12284
Eble JA, Berditchevski F (2001) Purification of integrins and characterization of integrin-associated proteins. In Methods in cell-matrix adhesion, Adams J (ed). San Diego: Academic Press
Eble JA, Bruckner P, Mayer U (2003) Vipera lebetina venom contains two disintegrins inhibiting laminin-binding b1 integrins. J Biol Chem 278: 26488-26496
Eble JA, Golbik R, Mann K, Kühn K (1993) The a1b1 integrin recognition site of the basement membrane collagen molecule [a1(IV)]2a2(IV). EMBO J 12(12): 4795-4802
Eble JA, Haier J (2006) Integrins in cancer treatment. Current Cancer Drug Targets 6(2): 89-105
Eble JA, Niland S, Bracht T, Mormann M, Peter-Katalinic J, Pohlentz G, Stetefeld J (2009) The 21 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. FASEB J 23(9): 2917-2927
Eble JA, Ries A, Lichý A, Mann L, Stanton H, Gavrilovic J, Murphy G, Kühn K (1996) The recognition sites of the integrins 11 and 21 within collagen IV are protected against gelatinase A attach in the native protein. J Biol Chem 271: 30964-30970
Eble JA, Tuckwell DS (2003) The 21 integrin inhibitor rhodocetin binds to the A-domain of the integrin 2 subunit proximal to the collagen binding site. Biochem J 376: 77-85
Eble JA, Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME (1998) Recombinant soluble human 31 integrin: purification, regulation, and specific binding to laminin-5 and invasin in a mutualy exclusive manner. Biochem 37(31): 10945-10955
Fiedler LR, Schönherr E, Waddington R, Niland S, Seidler DG, Äschlimann D, Eble JA (2008) Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of 21 integrin activity. J Biol Chem 283: 17406-17415
Fortunati E, Ehlert E, van Loo N-D, Wyman C, Eble JA, Grosveld F, Scholte BJ (2000) A multi-domain protein for 1 integrin-targeted DNA delivery. Gene Therapy 7: 1505-1515
Fuller GLJ, Williams JAE, Tomlinson MG, Eble JA, Hanna SL, Pöhlmann S, Suzuki-Inoue K, Ozaki Y, Watson SP, Pearce AC (2007) The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem 282(17): 12397-12409
Golbik R, Eble JA, Ries A, Kühn K (2000) The spatial orientation of the essential amino acid residues arginine and aspartate within the 11 integrin recognition site of collagen IV has been resolved using fluorescence resonance energy transfer. J Mol Biol 297: 501-509
Hughes CE, Auger JM, McGlade J, Eble JA, Pearce AC, Watson SP (2008) Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2. J Thromb Haemost 6(12): 2152-2159
Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, O´Callaghan CA, Fütterer K, Watson SP (2010) CLEC-2 activates Syk through dimerisation. Blood 115(14): 2947-2955
Juárez P, Bolás G, de Rezende Figueiredo F, Calvete JJ, Eble JA (2010) Recombinant expression in human cells of active integrin 11-blocking RTS-disintegrin jerdostatin. Toxicon 56(6): 1052-1058
Kern A, Eble J, Golbik R, Kühn K (1993) Interaction of type IV collagen with the isolated integrins 11 and 21. Eur J Biochem 215: 151-159
Kerrigan AM, Dennehy KM, Mourao-Sá D, Faro-Trindade I, Wilment JA, Taylor PR, Eble JA, Reis e Sousa C, Brown GD (2009) CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophils. J Immunol 182(7): 4150-4157
Krähling H, Mally S, Eble JA, Noel J, Schwab A, Stock C (2009) The glycocalyx maintains a cell surface pH nanoenvironment crucial for integrin-mediated migration of human melanoma cells. Pflugers Arch Eur J Physiol 458(6): 1069-1083
Krukonis ES, Dersch P, Eble JA, Isberg RR (1998) Differential effects of integrin chain mutations on invasin and natural ligand interaction. J Biol Chem 273(48): 31837-31843
Kühn K, Eble J (1994) The structural bases of integrin-ligand interactions. Trends in Cell Biology 4: 256-261
Künneken K, Pohlentz G, Schmidt-Hederich A, Odenthal U, Smyth N, Peter-Katalinic J, Bruckner P, Eble JA (2004) Recombinant human laminin-5 domains; Effects of heterotrimerization, proteolytic processing, and N-glycosylation on 31 integrin binding. J Biol Chem 279(7): 5184-5193
Linn ML, Eble JA, Lübken C, Slade RW, Heino J, Suhrbier A (2004) An arthritogenic alphavirus uses the 11 integrin collagen receptor. Virology 336: 229-239
May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble JA, Elvers M, Nieswandt B (2009) CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 114(16): 3464-3472
Montesano R, Soulie P, Eble JA, Carrozzino F (2005) Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118(1): 3487-3500
Mori J, Pearce AC, Spalton JC, Grygielska B, Eble JA, Tomlinson MG, Senis YA, Watson SP (2008) G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. J Biol Chem 283(51): 35419-35427
Navdaev A, Heitmann V, deSantana Evangelista K, Mörgelin M, Wegener J, Eble JA (2008) The C-terminus of the 2 chain but not of the 3 chain of laminin-332 is indirectly but indispensibly necessary for integrin-mediated cell reactions. Exp Cell Res 314(3): 489-497
Perret S, Eble JA, Siljander P, Merle C, Farndale R, Theisen M, Ruggiero F (2003) Integrin 11 and platelet receptor GPVI collagen recognition is strictly dependent on prolyl hydroxylation. J Biol Chem 278: 29873-29879
Pollitt AY, Grygielska B, Leblond B, Désiré L, Eble JA, Watson SP (2010) Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerisation, secondary mediators and Rac. Blood 115(14): 2938-2946
Ratzinger S, Eble JA, Pasoldt A, Opolka A, Rogler G, Grifka J, Grässel S (2010) Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. Matrix Biol 29(3): 177-193
Rosenow F, Ossig R, Thormeyer D, Gaßmann P, Schlüter K, Brunner G, Haier J, Eble JA (2008) Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis. Neoplasia 10(2): 168-176
Saccà B, Sinner E-K, Kaiser J, Lübken C, Eble JA, Moroder L (2002) Binding and docking of synthetic heterotrimeric collagen type IV peptides with 11 integrin. ChemBioChem 9: 904-907
Sanchez EF, Eble JA (2009) P-III metalloproteinase (leucurolysin-B) from Bothrops leucurus venom: isolation and possible inhibition. In Drug Design of Zinc-Enzyme Inhibitors, Supuran CT, Winum J-Y (eds), 33, pp 789-812. Chichester: John Wiley & Sons, Inc.
Sanchez EF, Gabriel LM, Gontijo S, Gremski LH, Veiga SS, deSantana Evangelista K, Eble JA, Richardsom M (2007) Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom. Arch Biochem Biophys 468(2): 193-204
Sanchez EF, Schneider FS, Yarleque A, Borges MH, Richardson M, Figueiredo Gomes S, De Santana Evangelista K, Eble JA (2010) The novel metalloproteinase, atroxlysin-I, from Peruvian Bothrops atrox (Jergón) snake venom acts on blood vessel ECM and platelets. Arch Biochem Biophys 496(1): 9-20
Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP (2009) The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost in press
Stock C, Gassner B, Hauck CR, Arnold H, Mally S, Eble JA, Dieterich P, Schwab A (2005) Migration of human melanoma cells depends on extracellular pH and Na+/H+ exchange. J Physiol 567(1): 225-238
Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP (2006) A novel syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 107(2): 542-549
Tanjoni I, Evangelista K, Della-Casa MS, Butera D, Magalhaes GS, Baldo C, Clissa PB, Fernandes I, Eble JA, Moura da Silva AM (2010) Different regions of jararhagin, a class P-III snake venom metalloproteinase, are involved in binding to 21 integrin and collagen. Toxicon 55(6): 1039-1099
Watson A, Brown J, Harlos K, Eble JA, Walter TS, O´Callaghan CA (2007) The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem 282(5): 3165-3172
Watson AA, Eble JA, O´Callaghan CA (2008) Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2. Protein Sci 17(9): 1611-1616
Woodall BP, Nyström A, Iozzo RA, Eble JA, Niland S, Krieg T, Eckes b, Pozzi A, Iozzo RV (2008) Integrin 21 is the required receptor for endorepellin angiostatic activity. J Biol Chem 283(4): 2335-2343
Zeltz C, Brézillin S, Käpylä J, Eble JA, Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX, Wegrowski Y (2010) Lumican inhibits cell migration through 21 integrin. Exp Cell Res 316(17): 2922-2931
Zigrino P, Kamiguti AS, Eble J, Drescher C, Nischt R, Fox JW, Mauch C (2002) The reprolysin jararhagin, a snake venom metalloproteinase, functions as a fibrillar collagen agonist involved in fibroblast cell adhesion and signalling. J Biol Chem 277: 40528-40535
Brown MC, Eble JA, Calvete JJ, Marcinkiewicz C (2009) Structural requirements of KTS-disintegrins for inhibition of a1b1 integrin. Biochem J 417(1): 95-101
De Santana Evangelista K, Andrich F, Figueiredo De Rezende F, Cordeiro MN, Niland S, Horlacher T, Schmidt-Hederich A, Seeberger P, Sanchez EF, Richardson M, Gomes De Figueiredo S, Eble JA (2010) Plumieribetin, a fish lectin homologous to monocot B-lectins, inhibits the collagen-binding a1b1 integrin. J Biol Chem 284(50): 34747-34758
Eble JA (1997) Integrins - a versatile and old family of cell adhesion molecules. In Integrin-Ligand Interaction, Eble JA, Kühn K (eds), pp 1-40. Heidelberg: Springer-Verlag
Eble JA (2001) The molecular basis of integrin-extracellular matrix interactions. Osteoarthritis and Cartilage 9(Suppl. A): S131-S140
Eble JA (2005) Collagen-binding integrins as pharmaceutical targets. Curr Pharm Design 11: 867-880
Eble JA (2006) Freie Fahrt fürs flüssige Blut: Gerinnungshemmende Wirkstoffe aus Schlangengiften. Chemie in unserer Zeit 40: 326-337
Eble JA (2007) Tumor cell-stroma cell interactions, Chapter 70. In The Cancer Handbook, Alison MR (ed), Vol. 2, pp 970-980. Chichester: John Wiley & Sons
Eble JA (2009) The extracellular matrix in health and disease. Curr Pharm Des 15(12): 5-6
Eble JA (2010) Matrix biology meets toxinology. Matrix Biol 29(4): 239-247
Eble JA, Beermann B, Hinz H-J, Schmidt-Hederich A (2001) a2b1 integrin is not recognized by rhodocytin but is the specific high affinity target of rhodocetin, an RGD-independent disintegrin and potent inhibitor of cell adhesion to collagen. J Biol Chem 276(15): 12274-12284
Eble JA, Berditchevski F (2001) Purification of integrins and characterization of integrin-associated proteins. In Methods in cell-matrix adhesion, Adams J (ed). San Diego: Academic Press
Eble JA, Bruckner P, Mayer U (2003) Vipera lebetina venom contains two disintegrins inhibiting laminin-binding b1 integrins. J Biol Chem 278: 26488-26496
Eble JA, Golbik R, Mann K, Kühn K (1993) The a1b1 integrin recognition site of the basement membrane collagen molecule [a1(IV)]2a2(IV). EMBO J 12(12): 4795-4802
Eble JA, Haier J (2006) Integrins in cancer treatment. Current Cancer Drug Targets 6(2): 89-105
Eble JA, Niland S, Bracht T, Mormann M, Peter-Katalinic J, Pohlentz G, Stetefeld J (2009) The 21 integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. FASEB J 23(9): 2917-2927
Eble JA, Ries A, Lichý A, Mann L, Stanton H, Gavrilovic J, Murphy G, Kühn K (1996) The recognition sites of the integrins 11 and 21 within collagen IV are protected against gelatinase A attach in the native protein. J Biol Chem 271: 30964-30970
Eble JA, Tuckwell DS (2003) The 21 integrin inhibitor rhodocetin binds to the A-domain of the integrin 2 subunit proximal to the collagen binding site. Biochem J 376: 77-85
Eble JA, Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME (1998) Recombinant soluble human 31 integrin: purification, regulation, and specific binding to laminin-5 and invasin in a mutualy exclusive manner. Biochem 37(31): 10945-10955
Fiedler LR, Schönherr E, Waddington R, Niland S, Seidler DG, Äschlimann D, Eble JA (2008) Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of 21 integrin activity. J Biol Chem 283: 17406-17415
Fortunati E, Ehlert E, van Loo N-D, Wyman C, Eble JA, Grosveld F, Scholte BJ (2000) A multi-domain protein for 1 integrin-targeted DNA delivery. Gene Therapy 7: 1505-1515
Fuller GLJ, Williams JAE, Tomlinson MG, Eble JA, Hanna SL, Pöhlmann S, Suzuki-Inoue K, Ozaki Y, Watson SP, Pearce AC (2007) The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem 282(17): 12397-12409
Golbik R, Eble JA, Ries A, Kühn K (2000) The spatial orientation of the essential amino acid residues arginine and aspartate within the 11 integrin recognition site of collagen IV has been resolved using fluorescence resonance energy transfer. J Mol Biol 297: 501-509
Hughes CE, Auger JM, McGlade J, Eble JA, Pearce AC, Watson SP (2008) Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2. J Thromb Haemost 6(12): 2152-2159
Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, O´Callaghan CA, Fütterer K, Watson SP (2010) CLEC-2 activates Syk through dimerisation. Blood 115(14): 2947-2955
Juárez P, Bolás G, de Rezende Figueiredo F, Calvete JJ, Eble JA (2010) Recombinant expression in human cells of active integrin 11-blocking RTS-disintegrin jerdostatin. Toxicon 56(6): 1052-1058
Kern A, Eble J, Golbik R, Kühn K (1993) Interaction of type IV collagen with the isolated integrins 11 and 21. Eur J Biochem 215: 151-159
Kerrigan AM, Dennehy KM, Mourao-Sá D, Faro-Trindade I, Wilment JA, Taylor PR, Eble JA, Reis e Sousa C, Brown GD (2009) CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophils. J Immunol 182(7): 4150-4157
Krähling H, Mally S, Eble JA, Noel J, Schwab A, Stock C (2009) The glycocalyx maintains a cell surface pH nanoenvironment crucial for integrin-mediated migration of human melanoma cells. Pflugers Arch Eur J Physiol 458(6): 1069-1083
Krukonis ES, Dersch P, Eble JA, Isberg RR (1998) Differential effects of integrin chain mutations on invasin and natural ligand interaction. J Biol Chem 273(48): 31837-31843
Kühn K, Eble J (1994) The structural bases of integrin-ligand interactions. Trends in Cell Biology 4: 256-261
Künneken K, Pohlentz G, Schmidt-Hederich A, Odenthal U, Smyth N, Peter-Katalinic J, Bruckner P, Eble JA (2004) Recombinant human laminin-5 domains; Effects of heterotrimerization, proteolytic processing, and N-glycosylation on 31 integrin binding. J Biol Chem 279(7): 5184-5193
Linn ML, Eble JA, Lübken C, Slade RW, Heino J, Suhrbier A (2004) An arthritogenic alphavirus uses the 11 integrin collagen receptor. Virology 336: 229-239
May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble JA, Elvers M, Nieswandt B (2009) CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 114(16): 3464-3472
Montesano R, Soulie P, Eble JA, Carrozzino F (2005) Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118(1): 3487-3500
Mori J, Pearce AC, Spalton JC, Grygielska B, Eble JA, Tomlinson MG, Senis YA, Watson SP (2008) G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. J Biol Chem 283(51): 35419-35427
Navdaev A, Heitmann V, deSantana Evangelista K, Mörgelin M, Wegener J, Eble JA (2008) The C-terminus of the 2 chain but not of the 3 chain of laminin-332 is indirectly but indispensibly necessary for integrin-mediated cell reactions. Exp Cell Res 314(3): 489-497
Perret S, Eble JA, Siljander P, Merle C, Farndale R, Theisen M, Ruggiero F (2003) Integrin 11 and platelet receptor GPVI collagen recognition is strictly dependent on prolyl hydroxylation. J Biol Chem 278: 29873-29879
Pollitt AY, Grygielska B, Leblond B, Désiré L, Eble JA, Watson SP (2010) Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerisation, secondary mediators and Rac. Blood 115(14): 2938-2946
Ratzinger S, Eble JA, Pasoldt A, Opolka A, Rogler G, Grifka J, Grässel S (2010) Collagen XVI induces formation of focal contacts on intestinal myofibroblasts isolated from the normal and inflamed intestinal tract. Matrix Biol 29(3): 177-193
Rosenow F, Ossig R, Thormeyer D, Gaßmann P, Schlüter K, Brunner G, Haier J, Eble JA (2008) Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis. Neoplasia 10(2): 168-176
Saccà B, Sinner E-K, Kaiser J, Lübken C, Eble JA, Moroder L (2002) Binding and docking of synthetic heterotrimeric collagen type IV peptides with 11 integrin. ChemBioChem 9: 904-907
Sanchez EF, Eble JA (2009) P-III metalloproteinase (leucurolysin-B) from Bothrops leucurus venom: isolation and possible inhibition. In Drug Design of Zinc-Enzyme Inhibitors, Supuran CT, Winum J-Y (eds), 33, pp 789-812. Chichester: John Wiley & Sons, Inc.
Sanchez EF, Gabriel LM, Gontijo S, Gremski LH, Veiga SS, deSantana Evangelista K, Eble JA, Richardsom M (2007) Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom. Arch Biochem Biophys 468(2): 193-204
Sanchez EF, Schneider FS, Yarleque A, Borges MH, Richardson M, Figueiredo Gomes S, De Santana Evangelista K, Eble JA (2010) The novel metalloproteinase, atroxlysin-I, from Peruvian Bothrops atrox (Jergón) snake venom acts on blood vessel ECM and platelets. Arch Biochem Biophys 496(1): 9-20
Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP (2009) The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost in press
Stock C, Gassner B, Hauck CR, Arnold H, Mally S, Eble JA, Dieterich P, Schwab A (2005) Migration of human melanoma cells depends on extracellular pH and Na+/H+ exchange. J Physiol 567(1): 225-238
Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP (2006) A novel syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 107(2): 542-549
Tanjoni I, Evangelista K, Della-Casa MS, Butera D, Magalhaes GS, Baldo C, Clissa PB, Fernandes I, Eble JA, Moura da Silva AM (2010) Different regions of jararhagin, a class P-III snake venom metalloproteinase, are involved in binding to 21 integrin and collagen. Toxicon 55(6): 1039-1099
Watson A, Brown J, Harlos K, Eble JA, Walter TS, O´Callaghan CA (2007) The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem 282(5): 3165-3172
Watson AA, Eble JA, O´Callaghan CA (2008) Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2. Protein Sci 17(9): 1611-1616
Woodall BP, Nyström A, Iozzo RA, Eble JA, Niland S, Krieg T, Eckes b, Pozzi A, Iozzo RV (2008) Integrin 21 is the required receptor for endorepellin angiostatic activity. J Biol Chem 283(4): 2335-2343
Zeltz C, Brézillin S, Käpylä J, Eble JA, Bobichon H, Terryn C, Perreau C, Franz CM, Heino J, Maquart FX, Wegrowski Y (2010) Lumican inhibits cell migration through 21 integrin. Exp Cell Res 316(17): 2922-2931
Zigrino P, Kamiguti AS, Eble J, Drescher C, Nischt R, Fox JW, Mauch C (2002) The reprolysin jararhagin, a snake venom metalloproteinase, functions as a fibrillar collagen agonist involved in fibroblast cell adhesion and signalling. J Biol Chem 277: 40528-40535